Clinical Trial: Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07548450) titled 'Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)' on April 16.

Brief Summary: The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Waldenstrom Macroglobulinemia

Intervention: DRUG: Pirtobrutinib

200 mg daily

DRUG: Mosunetuzumab

Administered subcutaneously on day one of applicable cycles.

Recruitment Status: NOT_YET_RECRUI...